Myriad Genetics | MYGN - Operating Profit


Myriad Genetics reported $-3M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Agilent USD 444M 45M Jun/2026
Becton, Dickinson and Co. USD 752M 125M Jun/2026
Bio-Rad Laboratories USD 72.6M 38.5M Jun/2026
Bruker USD 69.6M 59.4M Jun/2026
Danaher USD 1.13B 217M Jun/2026
Illumina USD 260M 21M Jun/2026
J&J USD 7.48B 860M Jun/2026
Mettler Toledo International USD 287.55M 53.61M Jun/2026
Myriad Genetics USD -3M 20.3M Dec/2025
OraSure Technologies USD -13.59M 2.13M Dec/2025
Pacific Biosciences Of California USD -53.19M 35.08M Dec/2025
Quest Diagnostics USD 459M 60M Jun/2026
Quidel USD -15.3M 16.5M Jun/2026
Repligen USD 21.13M 1.15M Jun/2026
Revvity USD 126.14M 43.36M Jun/2026
Standard Biotools USD -9.42M 12.51M Mar/2026
Thermo Fisher Scientific USD 2.18B 273M Jun/2026
Veracyte USD 23.96M 4.88M Jun/2026
Waters USD -86M 234M Jun/2026